Within group analyses demonstrated improvement in symptomology from baseline to followup in patients undergoing group ( mean SD 3.6 7.6 , p = 0.03 , 95 % CI 0.4-6 .8 ) and individual urotherapy ( 6.0 5.4 , p < 0.01 , 95 % CI 3.8-8 .3 ) .